Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19);New preclinical data demonstrate robust immunogenicity with a single, low dose Company remains.

100% of animals seroconverted by day 19 at a low dose (2 µg)LUNAR-COV19 remains on track to initiate human clinical trials this Summer SAN DIEGO, April 27, 2020 -- Arcturus.

The enormity of the coronavirus pandemic has forced biopharma companies to step up efforts to expeditiously develop vaccines and treatments for COVID-19. The Frontrunners Moderna Inc (NASDAQ: MRNA), which was the first company to move its coronavirus vaccine candidate to the clinics, said in mid-March that the first participant has been dosed in an NIH-led, Phase 1 study of its mRNA vaccine in the U.S.Inovio Pharmaceuticals Inc (NASDAQ: INO) announced earlier this week that it is initiating a Phase 1 study to test its DNA vaccine for the coronavirus following the FDA's acceptance of Inovio's IND application.Apart from these companies, CanSino Biologics and the Academy of Military Sciences are running Phase 1 trials of their non-replicating vaccine candidate in China.The University of Oxford is testing a chimpanzee adeno vector vaccine candidate in a Phase 1/2 trial in the U.K.Novavax, Inc. (NASDAQ: NVAX) said Wednesday it has identified a vaccine candidate and is planning to initiate human trials in mid-May.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See also: How The COVID-19 Outbreak Is Benefiting Biotech Investors Pfizer, BioNTech Make Progress Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX), which initially announced a collaboration to develop a COVID-19 vaccine on March 17, released further details on the partnership Thursday. The companies said they are looking to rapidly advance multiple candidates into human clinical testing based on BioNTech's proprietary mRNA vaccine platforms and leveraging Pfizer's expertise in vaccine R&D, regulatory capabilities and a global manufacturing and distribution network.The clinical trials are planned to be conducted across multiple sites in the U.S. and Europe. Pfizer and BioNTech said they expect to start the first clinical trial as early as the end of April, contingent upon the receipt of regulatory clearance. The collaboration agreement calls for Pfizer to pay BioNTech $185 million in upfront payments, including a cash payment of $72 million and an equity investment of $113 million.BioNTech also stands to receive future milestone payments of up to $563 million for a potential total consideration of $748 million.Arcturus Targets Summer Start For Human Trials Arcturus Therapeutics Ltd (NASDAQ: ARCT), an mRNA medicines company, said Thursday it plans to initiate human trials of its COVID-19 vaccine candidate -- LUNAR-COV19 -- this summer.The company said under the guidance of the Health Sciences Authority of Singapore, it plans to start the trial, enrolling 76 healthy volunteer adults, with follow-up over several months to evaluate the extent and duration of immune response.LUNAR-COV19 is a potential single-shot, self-replicating mRNA vaccine devoid of any viral material or co-adjuvants, according to Arcturus. The company said the vaccine candidate is being manufactured, with the initial GMP batch to be delivered in June.PFE, ARCT, BNTX Price Action Pfizer shares were up 2.69% at $35.54 at the time of publication Thursday, while BioNTech shares were up 2.58% at $46.11. Arcturus shares were rising 8.28% to $14.90. Related Link: Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall * The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO * The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Arcturus Therapeutics (ARCT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -55.10% and -34.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, May 04, 2020 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on.

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than.

SAN DIEGO, March 27, 2020 -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines and vaccines company, today provided details about the.

Image source: The Motley Fool. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)Q1 2020 Earnings CallMay 07, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welcome to the Arcturus Therapeutics conference call.

Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus. LUNAR-COV19 utilizes Arcturus’ self-transcribing and replicating mRNA (STARR™) technology and the Company’s LUNAR® lipid-mediated delivery to produce an extraordinarily low dose, potential single shot COVID-19 vaccine.

Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced the closing on April 20, 2020 of its previously announced underwritten public offering of 4,735,297 shares of its common stock at a price of $17.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 617,647 additional shares of common stock. Arcturus received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of $80,500,049. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes, which may include capital expenditures and research and development expenditures related to the advancement of LUNAR-OTC, LUNAR-COV19 and its other product candidates and clinical trial expenditures.

Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. In addition, the Company intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

Ultragenyx Pharmaceutical, Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc. (ARCT), a leading messenger RNA medicines company, today announced that Ultragenyx has exercised its option to purchase 600,000 shares of Arcturus common stock at $16.00 per share. “We are encouraged by the advancement of Arcturus’s broad nucleic acid platform across multiple therapeutic areas, including their self-replicating mRNA-based COVID-19 vaccine candidate,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.

NEW YORK, NY / ACCESSWIRE / March 11, 2020 / Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, ...

IND Filed for Flagship Program ARCT-810Coronavirus Vaccine Program InitiatedInvestor Conference Call at 4:30 pm ET Today SAN DIEGO, Calif., March 11, 2020 -- Arcturus.

Shares of Arcturus Therapeutics (NASDAQ: ARCT) were plunging 32.3% as of 11:43 a.m. EDT on Wednesday. Reports surfaced yesterday that one of the participants in Moderna's phase 1 study of its COVID-19 vaccine candidate experienced a severe reaction. STAT News' Matthew Herper reported on Tuesday that Ian Haydon developed a high fever after receiving a second dose of Moderna's experimental COVID-19 vaccine.

Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN.

One of the biggest stories of last week was how Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares plunged 48...

GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO, April 09, 2020 -- Arcturus Therapeutics (the “Company”, NASDAQ:.

Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the pricing of an underwritten public offering of 4,117,650 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $70 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 617,647 shares of common stock at the public offering price, less underwriting discounts and commissions.